PATENT CLAIM ANALYSIS

Application Number: 15945664
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-04
Patent Classification: ["514", "318000"]

Abstract:
Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognition, motor, or other neurodegenerative-affected function. Cognitive and motor diseases upon which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, progressive supranuclear palsy.

Claim (Index 1):
A method of treating neurodegenerative disease in a subject diagnosed with the neurodegenerative disease, the method comprising administering a therapeutically effective amount of a compound of formula 1, wherein A is CH 2 , O or N\u2014C 1-6 -alkyl; R 1  is selected from\n NHR 1.1 , NMeR 1.1 ; \n NHR 1.2 , NMeR 1.2 ; \n NHCH 2 \u2014R 1.3 ; \n NH\u2014C 3-6 -cycloalkyl, whereas optionally one carbon atom is replaced by a nitrogen atom, whereas the ring is optionally substituted with one or two residues selected from the group consisting of C 1-6 -alkyl, O\u2014C 1-6 -alkyl, NHSO 2 -phenyl, NHCONH-phenyl, halogen, CN, SO 2 \u2014C 1-6 -alkyl, COO\u2014C 1-6 -alkyl; \n a C 9 or 10 -bicyclic-ring, whereas one or two carbon atoms are replaced by nitrogen atoms and the ring system is bound via a nitrogen atom to the basic structure of formula 1 and whereas the ring system is optionally substituted with one or two residues selected from the group consisting of C 1-6 -alkyl, COO\u2014C 1-6 -alkyl, C 1-6 -haloalkyl, O\u2014C 1-6 -alkyl, NO 2 , halogen, CN, NHSO 2 \u2014C 1-6 -alkyl, methoxy-phenyl; \n a group selected from NHCH(pyridinyl)CH 2 COO\u2014C 1-6 -alkyl, NHCH(CH 2 O\u2014C 1-6 -alkyl)-benzoimidazolyl, optionally substituted with halogen or CN; \n or 1-aminocyclopentyl, optionally substituted with methyl-oxadiazole; \n R 1.1  is phenyl, optionally substituted with one or two residues selected from the group consisting of C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 1-6 -haloalkyl, C 1-6 -alkylene-OH, C 2-6 -alkenylene-OH, C 2-6 -alkynylene-OH, CH 2 CON(C 1-6 -alkyl) 2 , CH 2 NHCONH\u2014C 3-6 -cycloalkyl, CN, CO-pyridinyl, CONR 1.1.1 R 1.1.2 , COO\u2014C 1-6 -alkyl, N(SO 2 \u2014C 1-6 -alkyl)(CH 2 CON(C 1-4 -alkyl) 2 )O\u2014C 1-6 -alkyl, O-pyridinyl, SO 2 \u2014C 1-6 -alkyl, SO 2 \u2014C 1-6 -alkylen-OH, SO 2 \u2014C 3-6 -cycloalkyl, SO 2 -piperidinyl, SO 2 NH\u2014C 1-6 -alkyl, SO 2 N(C 1-6 -alkyl) 2 , halogen, CN, CO-morpholinyl, CH 2 -pyridinyl or a heterocyclic ring optionally substituted with one or two residues selected from the group consisting of C 1-6 -alkyl, NHC 1-6 -alkyl and \u2550O;\n R 1.1.1  H, C 1-6 -alkyl, C 3-6 -cycloalkyl, C 1-6 -haloalkyl, CH 2 CON(C 1-6 -alkyl) 2 , CH 2 CO-azetindinyl, C 1-6 -alkylen-C 3-6 -cycloalkyl, CH 2 -pyranyl, CH 2 -tetrahydrofuranyl, CH 2 -furanyl, C 1-6 -alkylen-OH or thiadiazolyl, optionally substituted with C 1-6 -alkyl; \n R 1.1.2  H, C 1-6 -alkyl, SO 2 C 1-6 -alkyl; \n \n \u2003or R 1.1.1  and R 1.1.2  together are forming a four-, five- or six-membered carbocyclic ring, optionally containing one N or O, replacing a carbon atom of the ring, optionally substituted with one or two residues selected from the group consisting of C 1-6 -alkyl, C 1-4 -alkylene-OH, OH, \u2550O; \n \u2003or \n R 1.1  is phenyl, wherein two adjacent residues are together forming a five- or six-membered carbocyclic aromatic or non-aromatic ring, optionally containing independently from each other one or two N, S, or SO 2 , replacing a carbon atom of the ring, wherein the ring is optionally substituted with C 1-4 -alkyl or \u2550O; \n R 1.2  is selected from\n heteroaryl, optionally substituted with one or two residues selected from the group consisting of C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-6 -cycloalkyl, CH 2 COO\u2014C 1-6 -alkyl, CONR 1.2.1 R 1.2.2 , COR 1.2.3 , COO\u2014C 1-6 -alkyl, CONH 2 , O\u2014C 1-6 -alkyl, halogen, CN, SO 2 N(C 1-6 -alkyl) 2  or heteroaryl optionally substituted with one or two residues selected from the group consisting of C 1-6 -alkyl; \n heteroaryl, optionally substituted with a five- or six-membered carbocyclic non-aromatic ring containing independently from each other two N, O, S, or SO 2 , replacing a carbon atom of the ring; \n a aromatic or non-aromatic C 9 or 10 -bicyclic-ring, whereas one or two carbon atoms are replaced by N, O or S each optionally substituted with one or two residues selected from the group consisting of N(C 1-6 -alkyl) 2 , CONH\u2014C 1-6 -alkyl, \u2550O; \n a heterocyclic non-aromatic ring, optionally substituted with pyridinyl; \n 4,5-dihydro-naphtho[2,1-d]thiazole, optionally substituted with NHCO\u2014C 1-6 -alkyl, \n R 1.2.1  H, C 1-6 -alkyl, C 1-6 -alkylene-C 3-6 -cycloalkyl, C 1-4 -alkylene-phenyl, C 1-4 -alkylene-furanyl, C 3-6 -cycloalkyl, C 1-4 -alkylene-O\u2014C 1-4 -alkyl, C 1-6 -haloalkyl or a five- or six-membered carbocyclic non-aromatic ring, optionally containing independently from each other one or two N, O, S, or SO 2 , replacing a carbon atom of the ring, optionally substituted with 4-cyclopropylmethyl-piperazinyl \n R 1.2.2  H, C 1-6 -alkyl; \n R 1.2.3  a five- or six-membered carbocyclic non-aromatic ring, optionally containing independently from each other one or two N, O, S, or SO 2 , replacing a carbon atom of the ring; \n \n R 1.3  is selected from phenyl, heteroaryl or indolyl, each optionally substituted with one or two residues selected from the group consisting of C 1-6 -alkyl, C 3-6 -cycloalkyl, O\u2014C 1-6 -alkyl, O\u2014C 1-6 -haloalkyl, phenyl, heteroaryl; \n R 2  is selected from the group consisting of C 1-6 -alkylene-phenyl, C 1-6 -alkylene-naphthyl, and C 1-6 -alkylene-heteroaryl; each optionally substituted with one, two or three residues selected from the group consisting of C 1-6 -alkyl, C 1-6 -haloalkyl, O\u2014C 1-6 -alkyl, O\u2014C 1-6 -haloalkyl, halogen; R 3  is H, C 1-6 -alkyl; R 4  is H, C 1-6 -alkyl;\n or R 3  and R 4  together are forming a CH 2 \u2014CH 2  group; \n to treat the subject for the neurodegenerative disease.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 91.0
- Lexical Diversity: 1.55932
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12727318', '13596225', '12812940', '12402910', '12616094']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7998539966986319
- 35 USC 102 Novelty (BERT): 0.5050824852360419
- Combined Prediction Score: 0.770376845552373
- Mean Citation Score: 280.20747400000005
- Max Citation Score: 298.24933
- Similarity Product: 247.485910325675

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test